Alport's syndrome

6 trials 2 recruiting MedDRA PT
6 Registered trials
2 Recruiting
6 Unique sponsors
6 Unique IMPs
5 Commercial trials
Drug classes (ATC)
— ATC code not specified 5
A Gastroenterology (ATC A) 1
N Neurology/Psychiatry (ATC N) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 5 substances
SGLT2 inhibitor 1 substance
Phase III: 1 Phase II: 4 Phase I: 1

Filter these 6 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 6 trials

Phase III

1 trial
  • Universitaetsmedizin Goettingen Academic
    DAPAGLIFLOZIN; PLACEBO
    2023-508502-18-00 1 country 2024 n=102
    Recruiting

Phase II

4 trials
  • Calliditas Therapeutics Suisse S.A. Commercial
    SETANAXIB
    2023-505292-73-00 6 countries 2024 n=28
    Ended
  • ENYO Pharma Commercial
    VONAFEXOR
    2023-509638-20-00 3 countries 2024 n=13 Orphan
    Ended
  • River 2 Renal Corp. Commercial
    R3R01
    2024-512964-73-00 4 countries 2023 n=20
    Ended
  • Travere Therapeutics Inc. Commercial
    SPARSENTAN
    2023-505497-14-00 6 countries 2021 n=27 Orphan
    Recruiting

Phase I

1 trial
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Bayer AG Commercial 1 Phase I 0
Calliditas Therapeutics Suisse S.A. Commercial 1 Phase II 0
ENYO Pharma Commercial 1 Phase II 0
River 2 Renal Corp. Commercial 1 Phase II 0
Travere Therapeutics Inc. Commercial 1 Phase II 1
Universitaetsmedizin Goettingen Academic 1 Phase III 1
New trials by year
2021
1
2023
2
2024
3
← All indication landscapes